Global R&D Pipeline
My Favorite
Hot Targets:
SEZ6
Back
Total number of drugs
5
Phase II and later clinical stages
20%
Involving companies
7
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV-706 | ABBV-706 | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases | SEZ6 inhibitors TOP1 inhibitors | AbbVie, Inc. | AbbVie, Inc. | Phase 2/3 | Phase 1 | - | - | - | Orphan Drug（United States） | - | - | - | - | ABBV-706 | - | - | detail > | |
| DLL3xSEZ6 bsADC(Biocytogen) | DLL3xSEZ6 bsADC(Biocytogen) | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases | DLL3 inhibitors SEZ6 inhibitors TOP1 inhibitors | Biocytogen Boston Corp. | Biocytogen Boston Corp. | Preclinical | - | - | - | - | - | - | Cleavable linker | - | 8 | DLL3xSEZ6 bsADC(Biocytogen) | - | - | detail > | |
| DEC-002 | DEC-002 | Antibody drug conjugate (ADC) | Neoplasms | SEZ6 inhibitors | WuXi AppTec Biotechnology Co., Ltd. Hangzhou DAC Biotechnology Co., Ltd. | WuXi AppTec Biotechnology Co., Ltd. Whitehawk Therapeutics, Inc. Hangzhou DAC Biotechnology Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | DEC-002 | - | - | detail > | |
| HWK-206 | HWK-206 | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases | SEZ6 modulators | Whitehawk Therapeutics, Inc. | Whitehawk Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | HWK-206 | - | - | detail > | |
| SC-011 | SC-011 | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases | DNA inhibitors SEZ6 inhibitors | AbbVie, Inc. | - | Discontinued (in Phase 1) | - | - | - | - | Orphan Drug（European Union） | - | Non-cleavable linker | N-Acetyl-Gamma Calicheamicin | 2 | SC-011 | IgG1 - nd | - | detail > |
Total 5 data
1
